Crewe Advisors LLC Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Crewe Advisors LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,115 shares of the biopharmaceutical company’s stock after selling 560 shares during the period. Crewe Advisors LLC’s holdings in Gilead Sciences were worth $103,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Tectonic Advisors LLC grew its holdings in shares of Gilead Sciences by 7.4% during the fourth quarter. Tectonic Advisors LLC now owns 81,286 shares of the biopharmaceutical company’s stock valued at $7,508,000 after buying an additional 5,580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Gilead Sciences by 8.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 434,165 shares of the biopharmaceutical company’s stock valued at $40,689,000 after buying an additional 34,549 shares during the last quarter. Y.D. More Investments Ltd grew its holdings in shares of Gilead Sciences by 43.3% during the fourth quarter. Y.D. More Investments Ltd now owns 1,602 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 484 shares during the last quarter. Hager Investment Management Services LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $145,000. Finally, Stratos Investment Management LLC grew its holdings in shares of Gilead Sciences by 6.2% during the fourth quarter. Stratos Investment Management LLC now owns 2,895 shares of the biopharmaceutical company’s stock valued at $267,000 after buying an additional 170 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on GILD shares. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $74.00 to $96.00 in a report on Monday, October 21st. BMO Capital Markets upped their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Robert W. Baird upped their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Oppenheimer upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Monday. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Stock Down 1.6 %

GILD opened at $98.04 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50-day moving average price of $92.86 and a 200 day moving average price of $86.41. The company has a market cap of $122.18 billion, a PE ratio of 1,089.33, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.